US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
EP0920505B1
(en)
*
|
1996-08-16 |
2008-06-04 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
GB9625074D0
(en)
*
|
1996-12-02 |
1997-01-22 |
Pharmacia & Upjohn Spa |
Receptor belonging to the TNF/NGF receptor family
|
US6503184B1
(en)
|
1997-10-21 |
2003-01-07 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
US6689607B2
(en)
|
1997-10-21 |
2004-02-10 |
Human Genome Sciences, Inc. |
Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
CA2308114A1
(en)
*
|
1997-10-21 |
1999-04-29 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
CA2319236A1
(en)
*
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
JP2002537769A
(ja)
|
1999-02-26 |
2002-11-12 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトエンドカインαおよび使用方法
|
PT1196186E
(pt)
*
|
1999-07-12 |
2008-02-14 |
Genentech Inc |
Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
|
JP2003530847A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
US7138501B2
(en)
|
2000-06-16 |
2006-11-21 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind BLyS
|
WO2002097033A2
(en)
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
JP5424521B2
(ja)
|
2001-12-21 |
2014-02-26 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
ES2432091T5
(es)
|
2005-03-25 |
2022-03-18 |
Gitr Inc |
Moléculas de unión GITR y usos de las mismas
|
KR20140077946A
(ko)
|
2005-10-13 |
2014-06-24 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
MX2009012143A
(es)
|
2007-05-23 |
2010-03-01 |
Tokuyama Corp |
Dispositivo para recubrimiento de lentes.
|
WO2009009116A2
(en)
|
2007-07-12 |
2009-01-15 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
CN102227503B
(zh)
|
2008-09-26 |
2015-10-21 |
托卡根公司 |
重组载体
|
CN103951753B
(zh)
|
2009-09-03 |
2018-01-12 |
默沙东公司 |
抗‑gitr抗体
|
US8956859B1
(en)
|
2010-08-13 |
2015-02-17 |
Aviex Technologies Llc |
Compositions and methods for determining successful immunization by one or more vaccines
|
AR084141A1
(es)
|
2010-11-19 |
2013-04-24 |
Imai Toshio |
Anticuerpos neutralizadores anti-ccl20
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
JP5789206B2
(ja)
|
2011-12-08 |
2015-10-07 |
東京エレクトロン株式会社 |
ウエハ検査用インターフェース及びウエハ検査装置
|
US11065311B2
(en)
|
2012-10-25 |
2021-07-20 |
Denovo Biopharma Llc |
Retroviral vector with mini-promoter cassette
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
CN105899232A
(zh)
|
2013-11-13 |
2016-08-24 |
诺华股份有限公司 |
用于增强免疫应答的mTOR抑制剂
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
ES2770684T3
(es)
|
2014-03-14 |
2020-07-02 |
Novartis Ag |
Moléculas de anticuerpos contra LAG-3 y usos de los mismos
|
CN106163547A
(zh)
|
2014-03-15 |
2016-11-23 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
PE20161371A1
(es)
|
2014-03-24 |
2016-12-21 |
Novartis Ag |
Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas
|
JP6765966B2
(ja)
|
2014-04-07 |
2020-10-07 |
ノバルティス アーゲー |
抗cd19キメラ抗原受容体を使用する癌の処置
|
DK3151921T3
(da)
|
2014-06-06 |
2019-12-02 |
Bristol Myers Squibb Co |
Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
|
DK3166973T3
(da)
|
2014-07-10 |
2020-04-06 |
Univ Zuerich |
Immunstimulerende monoklonale antistoffer mod human interleukin-2
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
RU2751660C2
(ru)
|
2014-07-21 |
2021-07-15 |
Новартис Аг |
Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
US10160726B2
(en)
|
2014-08-06 |
2018-12-25 |
Novartis Ag |
Quinolone derivatives as antibacterials
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
LT3183268T
(lt)
|
2014-08-19 |
2020-06-10 |
Novartis Ag |
Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
|
US11344620B2
(en)
|
2014-09-13 |
2022-05-31 |
Novartis Ag |
Combination therapies
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
WO2016054555A2
(en)
|
2014-10-03 |
2016-04-07 |
Novartis Ag |
Combination therapies
|
JP6815992B2
(ja)
|
2014-10-08 |
2021-01-20 |
ノバルティス アーゲー |
キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
PE20171067A1
(es)
|
2014-10-14 |
2017-07-24 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
MA41185B1
(fr)
|
2014-12-16 |
2019-12-31 |
Novartis Ag |
Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
RU2021118125A
(ru)
|
2014-12-29 |
2022-04-06 |
Новартис Аг |
Способы получения экспрессирующих химерный антигенный рецептор клеток
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
BR112017018908A2
(pt)
|
2015-03-10 |
2018-04-17 |
Aduro Biotech, Inc. |
composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
SI3280729T1
(sl)
|
2015-04-08 |
2022-09-30 |
Novartis Ag |
Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
|
CA2982996A1
(en)
|
2015-04-17 |
2016-10-20 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
EP3304079B1
(en)
|
2015-06-03 |
2020-06-03 |
Bristol-Myers Squibb Company |
Anti-gitr antibodies for cancer diagnostics
|
TW201708538A
(zh)
|
2015-07-21 |
2017-03-01 |
諾華公司 |
改良免疫細胞之功效及擴展之方法
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
MX2018005550A
(es)
|
2015-11-03 |
2019-07-18 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a tim-3 y sus usos.
|
WO2017087678A2
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
TW201731872A
(zh)
|
2015-12-18 |
2017-09-16 |
諾華公司 |
標靶CD32b之抗體及其使用方法
|
JP7082055B2
(ja)
|
2015-12-22 |
2022-06-07 |
ノバルティス アーゲー |
抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体
|
SG11201805449PA
(en)
|
2015-12-28 |
2018-07-30 |
Novartis Ag |
Methods of making chimeric antigen receptor -expressing cells
|
EA039865B1
(ru)
|
2016-01-11 |
2022-03-22 |
Универзитет Цюрих |
Иммуностимулирующее гуманизированное моноклональное антитело против интерлейкина-2 человека и слитый белок
|
UY37128A
(es)
|
2016-02-19 |
2017-09-29 |
Novartis Ag |
Compuestos tetracíclicos de piridona como antivirales
|
MX2018010733A
(es)
|
2016-03-04 |
2019-07-04 |
Novartis Ag |
Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
|
US9988416B2
(en)
|
2016-03-24 |
2018-06-05 |
Novartis Ag |
Alkynyl nucleoside analogs as inhibitors of human rhinovirus
|
EP3432927A4
(en)
|
2016-03-24 |
2019-11-20 |
Gensun Biopharma Inc. |
TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
|
BR112018075434A2
(pt)
|
2016-06-10 |
2019-03-19 |
Regeneron Pharmaceuticals, Inc. |
anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.
|
MD3468957T2
(ro)
|
2016-06-14 |
2020-11-30 |
Novartis Ag |
Formă cristalină a (R)-4-(5-(ciclopropiletinil)izoxazol-3-il)-N-hidroxi-2-metil-2-(metilsulfonil)butanamidei în calitate de agent antibacterian
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
UA125216C2
(uk)
|
2016-06-24 |
2022-02-02 |
Інфініті Фармасьютікалз, Інк. |
Комбінована терапія
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
KR102565885B1
(ko)
|
2016-07-20 |
2023-08-09 |
유니버시티 오브 유타 리서치 파운데이션 |
Cd229 car t 세포 및 이의 사용 방법
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
WO2018057585A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
US10525083B2
(en)
|
2016-10-07 |
2020-01-07 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
BR112019011065A2
(pt)
|
2016-12-03 |
2019-10-01 |
Juno Therapeutics Inc |
métodos para determinação da dosagem de células t car
|
MX2019007643A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibirores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal.
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
AU2018249493A1
(en)
|
2017-04-03 |
2019-09-19 |
Oncxerna Therapeutics, Inc. |
Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
AR111658A1
(es)
|
2017-05-05 |
2019-08-07 |
Novartis Ag |
2-quinolinonas tricíclicas como agentes antibacteriales
|
KR20200006115A
(ko)
|
2017-05-16 |
2020-01-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-gitr 효능제 항체에 의한 암의 치료
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
KR20200041834A
(ko)
|
2017-06-01 |
2020-04-22 |
젠코어 인코포레이티드 |
Cd123 및 cd3에 결합하는 이중특이성 항체
|
KR20200054160A
(ko)
|
2017-06-02 |
2020-05-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
|
US11572541B2
(en)
|
2017-06-09 |
2023-02-07 |
Providence Health & Services—Oregon |
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
|
CA3067602A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
BR112020007710A2
(pt)
|
2017-10-25 |
2020-10-20 |
Novartis Ag |
métodos para produzir células que expressam receptor de antígeno quimérico
|
WO2019089969A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
CN112204048A
(zh)
|
2017-12-15 |
2021-01-08 |
朱诺治疗学股份有限公司 |
抗cct5结合分子及其使用方法
|
WO2019123285A1
(en)
|
2017-12-20 |
2019-06-27 |
Novartis Ag |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
CN111801331A
(zh)
|
2018-02-28 |
2020-10-20 |
诺华股份有限公司 |
吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
US11090304B2
(en)
|
2018-05-04 |
2021-08-17 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
US11045484B2
(en)
|
2018-05-04 |
2021-06-29 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
JP7361720B2
(ja)
|
2018-05-10 |
2023-10-16 |
アムジエン・インコーポレーテツド |
がんの治療のためのkras g12c阻害剤
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
WO2019232528A1
(en)
|
2018-06-01 |
2019-12-05 |
Xencor, Inc. |
Dosing of a bispecific antibody that bind cd123 and cd3
|
MX2020012731A
(es)
|
2018-06-01 |
2021-02-22 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
US20190375749A1
(en)
|
2018-06-11 |
2019-12-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
MX2020013443A
(es)
|
2018-06-13 |
2021-02-26 |
Novartis Ag |
Receptores de antigeno quimerico de bcma y usos de los mismos.
|
EP3814381A4
(en)
|
2018-06-29 |
2022-08-10 |
Gensun Biopharma Inc. |
TRI-SPECIFIC ANTAGONISTS
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
JP2021534783A
(ja)
|
2018-08-31 |
2021-12-16 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
CA3107137A1
(en)
|
2018-09-07 |
2020-03-12 |
Pfizer Inc. |
Anti-avb8 antibodies and compositions and uses thereof
|
CA3112326A1
(en)
|
2018-09-12 |
2020-03-19 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
EP3856782A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
EP3856779A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd22 chimeric antigen receptor (car) therapies
|
BR112021005606A2
(pt)
|
2018-09-29 |
2021-06-22 |
Novartis Ag |
processo de produção de um composto para inibir a atividade de shp2
|
JP2022512917A
(ja)
|
2018-11-01 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
B細胞成熟抗原に特異的なキメラ抗原受容体を使用する処置方法
|
PE20211058A1
(es)
|
2018-11-01 |
2021-06-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
|
CN113271963A
(zh)
|
2018-11-16 |
2021-08-17 |
朱诺治疗学股份有限公司 |
给予工程化t细胞以治疗b细胞恶性肿瘤的方法
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
JP7454572B2
(ja)
|
2018-11-19 |
2024-03-22 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及びその使用方法
|
CA3120869A1
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
MA54547A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
JP7407196B2
(ja)
|
2018-12-20 |
2023-12-28 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
CN113365660A
(zh)
|
2019-01-29 |
2021-09-07 |
朱诺治疗学股份有限公司 |
对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
|
US20230096028A1
(en)
|
2019-03-01 |
2023-03-30 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
KR20210146287A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
WO2020236947A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
JP2022540571A
(ja)
|
2019-06-28 |
2022-09-16 |
ゲンスン バイオファーマ、インコーポレーテッド |
変異したTGFβ1-RII細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
|
EP4007756A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a inhibitors
|
CN114302880A
(zh)
|
2019-08-02 |
2022-04-08 |
美国安进公司 |
Kif18a抑制剂
|
JP2022542392A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤としてのピリジン誘導体
|
MX2022001296A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
CN114667285A
(zh)
|
2019-09-26 |
2022-06-24 |
诺华股份有限公司 |
抗病毒吡唑并吡啶酮化合物
|
JP2022552873A
(ja)
|
2019-10-24 |
2022-12-20 |
アムジエン・インコーポレーテツド |
がんの治療におけるkras g12c及びkras g12d阻害剤として有用なピリドピリミジン誘導体
|
KR20220109407A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
KR20220109406A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
EP4055017A1
(en)
|
2019-11-08 |
2022-09-14 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
AR120457A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
TW202134285A
(zh)
|
2019-11-26 |
2021-09-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
TW202140011A
(zh)
|
2020-01-07 |
2021-11-01 |
美商銳新醫藥公司 |
Shp2抑制劑給藥和治療癌症的方法
|
EP4104187A1
(en)
|
2020-02-14 |
2022-12-21 |
Novartis AG |
Method of predicting response to chimeric antigen receptor therapy
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
WO2021171264A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
Dosing of a bispecific antibody that binds cd123 and cd3
|
BR112022017156A2
(pt)
|
2020-03-06 |
2022-11-08 |
Regeneron Pharma |
Anticorpo isolado ou fragmento de ligação, molécula polinucleotídica isolada, vetor, célula hospedeira isolada, composição farmacêutica, método de tratamento de câncer, e, uso de um anticorpo
|
BR112022020333A2
(pt)
|
2020-04-10 |
2022-11-22 |
Juno Therapeutics Inc |
Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
TW202227460A
(zh)
|
2020-09-15 |
2022-07-16 |
美商銳新醫藥公司 |
Ras抑制劑
|
AU2021378316A1
(en)
|
2020-11-13 |
2023-06-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
EP4259149A1
(en)
|
2020-12-08 |
2023-10-18 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
TW202241885A
(zh)
|
2020-12-22 |
2022-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Sos1抑制劑及其用途
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
AR125782A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
US20220396589A1
(en)
|
2021-05-05 |
2022-12-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
AU2022288058A1
(en)
|
2021-06-07 |
2023-11-16 |
Agonox, Inc. |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
AU2022341239A1
(en)
|
2021-09-08 |
2024-03-21 |
Redona Therapeutics, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
TW202342474A
(zh)
|
2022-02-14 |
2023-11-01 |
美商基利科學股份有限公司 |
抗病毒吡唑并吡啶酮化合物
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
US20240041929A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|